HIV Infections
Conditions
Keywords
HIV-1 Infections
Brief summary
This study is to establish the clinical sensitivity of the Chembio Diagnostics Systems, Inc. Clearview COMPLETE HIV 1/2 Assay and Clearview HIV 1/2 Stat-Pak Assay (Clearview HIV tests) in pediatric subjects who are between 12 and 17 years of age. A minimum of ten (10) known HIV-positive participants will be tested.
Detailed description
In order to achieve the primary objective, clinical trials will be conducted to establish and confirm the sensitivity of the Clearview HIV 1/2 tests in the described pediatric population. Only HIV-1 will be included in the study. The Clearview HIV tests can be used as a safe and effective screening method to aid in the diagnosis of infection with HIV 1/2 in the pediatric population aged between 12 and 17 years. The secondary objectives of this study include demonstrating that: \- The Clearview HIV tests detect HIV-1 antibodies in a variety of sample matrices: capillary (fingertip) whole blood, venous whole blood, plasma and serum.
Interventions
None listed
Sponsors
Inverness Medical Innovations
University of Maryland
Focus Diagnostics, Inc.
Chembio Diagnostic Systems, Inc.
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Must be at least 12 years of age and no older than 17 years of age. * Must be willing to sign (and be given) a copy of the written Information and Assent Form. * Must have a parent or guardian present to sign and receive a copy of the Informed Consent Form. * Must be able to provide one or two fingerstick blood samples. * Must be able to provide three tubes of blood by venipuncture from the arm or hand only.
Exclusion criteria
* Have a life threatening illness (with the exception of HIV or AIDS). * Have a suppressed immune systems (i.e. transplant patients, individuals diagnosed with non-HIV immunosuppressive illness, etc.), as determined by interviewing the study participant or parent/legal guardian. * Have participated or are participating in a clinical trial for an HIV vaccine (as determined by interviewing the study participant or parent/legal guardian). * Have previously participated in this clinical trial (no duplicate enrollments). * Are currently on HAART, except as agreed on a case-by-case basis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Clearview HIV tests provide a 100% agreement with known HIV(+) status for all 10 eligible 12 to 17 year old individuals, at least one of whom will be age 12. | 3-10 days |
Secondary
| Measure | Time frame |
|---|---|
| The Clearview tests will be used in a representative clinical setting for the qualitative detection of antibodies to HIV-1 in fingerstick, venous whole blood, serum and plasma matrices. | 3-10 days |
Countries
United States
Outcome results
None listed